Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,8100113,tmax,"The pharmacokinetics profile of the compound can be described by a two-compartment open model, where the absorption and distribution phase were found to be rapid (tmax 0.5-1.0 hour in rats and 1.0-1.5 hours in humans).",[Pharmacokinetics and metabolism of tofizopam (Grandaxin)]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8100113/),h,0.5-1.0,5223,DB08811,Tofisopam
,8100113,tmax,"The pharmacokinetics profile of the compound can be described by a two-compartment open model, where the absorption and distribution phase were found to be rapid (tmax 0.5-1.0 hour in rats and 1.0-1.5 hours in humans).",[Pharmacokinetics and metabolism of tofizopam (Grandaxin)]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8100113/),h,1.0-1.5,5224,DB08811,Tofisopam
,8100113,biological half-life (t beta 1/2),"The unchanged tofizopam and 14C-total radioactivity were eliminated from human plasma with a biological half-life (t beta 1/2) of 2.7-3.5 hours and 15-21 hours, respectively, which show a slower elimination of the metabolites.",[Pharmacokinetics and metabolism of tofizopam (Grandaxin)]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8100113/),h,2.7-3.5,5225,DB08811,Tofisopam
,8100113,biological half-life (t beta 1/2),"The unchanged tofizopam and 14C-total radioactivity were eliminated from human plasma with a biological half-life (t beta 1/2) of 2.7-3.5 hours and 15-21 hours, respectively, which show a slower elimination of the metabolites.",[Pharmacokinetics and metabolism of tofizopam (Grandaxin)]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8100113/),h,15-21,5226,DB08811,Tofisopam
,16682162,recovery,The mean recovery for tofisopam was 69.8% and the inter- and intra-day precision values were well below the 15% limit established for bioanalytical methods.,Gas chromatography nitrogen phosphorous detection (GC-NPD) assay of tofisopam in human plasma for pharmacokinetic evaluation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16682162/),%,69.8,17744,DB08811,Tofisopam
,11933029,detection,"The detection limit (2 ng/mL), good precision (CV < or = 4.2%) and speed (total analysis time 24 min) of the present method were sufficient for drug monitoring.",Analysis of tofisopam in human serum by column-switching semi-micro high-performance liquid chromatography and evaluation of tofisopam bioequivalency. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11933029/),[ng] / [ml],2,272029,DB08811,Tofisopam
,11933029,total analysis time,"The detection limit (2 ng/mL), good precision (CV < or = 4.2%) and speed (total analysis time 24 min) of the present method were sufficient for drug monitoring.",Analysis of tofisopam in human serum by column-switching semi-micro high-performance liquid chromatography and evaluation of tofisopam bioequivalency. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11933029/),min,24,272030,DB08811,Tofisopam
